C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment

Journal of the American Society of Hypertension

Volumn 3, Issue 4, 2009, Pages 260-266

  Fulop, Tibor ^a   Rule, Andrew D ^b   Schmidt, Darren W ^a   Wiste, Heather J ^c   Bailey, Kent R ^c   Kullo, Iftikhar J ^b   Schwartz, Gary L ^b   Mosley Jr , Thomas H ^a   Boerwinkle, Eric ^d   Turner, Stephen T ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Diuretics; inflammation; RAAS inhibitors; sibships

Indexed keywords

ALBUMIN; ANTIDIURETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN INHIBITOR;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMMUNITY LIVING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ETHNICITY; FEMALE; GENDER; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 67650711094     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.03.003     Document Type: Article

References (29)

1. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 342 (2000) 836-843
2. Albert C.M., Ma J., Rifai N., Stampfer M.J., and Ridker P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105 (2002) 2595-2599
3. Pai J.K., Pischon T., Ma J., Manson J.E., Hankinson S.E., Joshipura K., et al. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med 51 (2004) 2599-2610
4. Ford E.S., and Giles W.H. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscl Thromb Vasc Biol 20 (2000) 1052-1056
5. Shlipak M.G., Fried L.F., Cushman M., Manolio T.A., Peterson D., Stehman-Breen C., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005) 1737-1745
6. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. New Engl J Med 355 (2006) 2631-2639
7. Bautista L.E., Lopez-Jaramillo P., Vera L.M., Casas J.P., Otero A.P., and Guaracao A.I. Is C-reactive protein an independent risk factor for essential hypertension?. J Hypertension 19 (2001) 857-861
8. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
9. Schillaci G., Pirro M., Gemelli F., Pasqualini L., Vaudo G., Marchesi S., et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertension 21 (2003) 1841-1846
10. Kullo I.J., Seward J.B., Bailey K.R., Bielak L.F., Grossardt B.R., Sheedy II P.F., et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 18 (2005) 1123-1129
11. Conen D., Zeller A., Pfisterer M., and Martina B. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Card 97 (2006) 249-252
12. Manabe S., Okura T., Watanabe S., Fukuoka T., and Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharm 46 (2005) 735-739
13. Amar J., Ruidavets J.B., Peyrieux J.C., Mallion J.M., Ferrieres J., Safar M.E., et al. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension 46 (2005) 151-155
14. Fliser D., Buchholz K., and Haller H. For the European trial on olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
15. Schram M.T., van Ittersum F.J., Spoelstra-de Man A., van Dijk R.A., Schalkwijk C.G., Ijzerman R.G., et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 19 (2005) 429-437
16. Palmas W., Ma S., Psaty B., Goff D.C., Darwin C., and Barr R.G. Antihypertensive Medications and C-reactive Protein in the Multi-Ethnic Study of Atherosclerosis. Am J Hypertens 20 (2007) 233-241
17. FBPP Investigators. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension 39 (2002) 3-9
18. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129 (1989) 687-702
19. Melton III L.J. History of the Rochester Epidemiology Project. Mayo Clin Proc 71 (1996) 266-274
20. Keevil B.G., Nicholls S.P., and Kilpatrick E.S. Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Ann Clin Biochem 35 (1998) 671-673
21. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., and Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
22. Godefroi R., Klementowicz P., Pepler C., Lewis B., McDonough K., and Goldberg R.J. Levels of, and factors associated with, C-reactive protein in employees attending a company-sponsored cardiac screening program. Cardiology 103 (2005) 180-184
23. Rogowski O., Shapira I., Shirom A., Melamed S., Toker S., and Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 93 (2007) 940-944
24. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Centers for Disease Control and Prevention. American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
25. Ridker P., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 336 (1997) 973-979
26. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
27. Pankow J.S., Folsom A.R., Cushman M., Borecki I.B., Hopkins P.N., Eckfeldt J.H., et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI Family Heart Study. Atherosclerosis 154 (2001) 681-689
28. Ding K., Feng D., de Andrade M., Mosley Jr. T.H., Turner S.T., Boerwinkle E., et al. Genomic regions that influence plasma levels of inflammatory markers in hypertensive sibships. J Hum Hypertens 22 (2008) 102-110
29. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47 (2001) 444-450